JP2015514778A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514778A5
JP2015514778A5 JP2015507173A JP2015507173A JP2015514778A5 JP 2015514778 A5 JP2015514778 A5 JP 2015514778A5 JP 2015507173 A JP2015507173 A JP 2015507173A JP 2015507173 A JP2015507173 A JP 2015507173A JP 2015514778 A5 JP2015514778 A5 JP 2015514778A5
Authority
JP
Japan
Prior art keywords
seq
composition
smad7
antisense oligonucleotide
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015507173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514778A (ja
JP6348484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/037150 external-priority patent/WO2013158868A1/en
Publication of JP2015514778A publication Critical patent/JP2015514778A/ja
Publication of JP2015514778A5 publication Critical patent/JP2015514778A5/ja
Application granted granted Critical
Publication of JP6348484B2 publication Critical patent/JP6348484B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015507173A 2012-04-18 2013-04-18 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法 Expired - Fee Related JP6348484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
US61/625,904 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018104372A Division JP2018131468A (ja) 2012-04-18 2018-05-31 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法

Publications (3)

Publication Number Publication Date
JP2015514778A JP2015514778A (ja) 2015-05-21
JP2015514778A5 true JP2015514778A5 (cg-RX-API-DMAC7.html) 2016-06-09
JP6348484B2 JP6348484B2 (ja) 2018-06-27

Family

ID=48326412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015507173A Expired - Fee Related JP6348484B2 (ja) 2012-04-18 2013-04-18 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法
JP2018104372A Pending JP2018131468A (ja) 2012-04-18 2018-05-31 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018104372A Pending JP2018131468A (ja) 2012-04-18 2018-05-31 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法

Country Status (14)

Country Link
US (3) US10081809B2 (cg-RX-API-DMAC7.html)
EP (1) EP2839004B1 (cg-RX-API-DMAC7.html)
JP (2) JP6348484B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150003824A (cg-RX-API-DMAC7.html)
CN (2) CN107252492A (cg-RX-API-DMAC7.html)
AU (1) AU2013249191B2 (cg-RX-API-DMAC7.html)
CA (1) CA2870547A1 (cg-RX-API-DMAC7.html)
DK (1) DK2839004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2732252T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN08158A (cg-RX-API-DMAC7.html)
MX (1) MX370149B (cg-RX-API-DMAC7.html)
NZ (1) NZ630914A (cg-RX-API-DMAC7.html)
RU (1) RU2667960C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013158868A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2704092T3 (es) * 2014-04-30 2019-03-14 Procter & Gamble Composición limpiadora
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
JP7495126B2 (ja) * 2018-05-08 2024-06-04 ユニヴァーシティー オブ マイアミ 組織への治療用核酸の送達のための材料および方法
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP3604537B1 (en) 2003-06-13 2021-12-08 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
KR101357016B1 (ko) 2004-09-28 2014-02-03 쿠아크 파마수티칼스 인코퍼레이티드 탈모증, 급성신부전증 및 다른 질환의 치료를 위한올리고리보뉴클레오티드 및 그것의 사용방법
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
WO2009129544A1 (en) * 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
EP3693736A3 (en) 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Similar Documents

Publication Publication Date Title
JP2015514778A5 (cg-RX-API-DMAC7.html)
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
JP2015511821A5 (cg-RX-API-DMAC7.html)
MX339002B (es) El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
GB2491328A (en) Immediate/delayed drug delivery
MX359548B (es) Agentes de iarn modificados.
WO2009090639A3 (en) Sirna compounds and methods of use thereof
AR084319A1 (es) INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
CR11723A (es) Agente para tratar enfermedad
GB2491327A (en) Delayed prolonged drug delivery
MX373926B (es) Metodos para tratar cancer y estados no neoplasicos.
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
JP2014501492A5 (cg-RX-API-DMAC7.html)
JP2012514021A5 (cg-RX-API-DMAC7.html)
JP2016517401A5 (cg-RX-API-DMAC7.html)
IN2014DN10390A (cg-RX-API-DMAC7.html)
BR112014032239A2 (pt) inibidores da família de mir-15 de micro-rnas
RU2015140572A (ru) Способы лечения колоректального рака
JP2012516879A5 (cg-RX-API-DMAC7.html)
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.
MX342020B (es) Apolipoproteina a-iv como un peptido antidiabetico.
JP2013520447A5 (cg-RX-API-DMAC7.html)